Clinical Trials Directory

Trials / Completed

CompletedNCT00952952

Trial of Mesalamine for the Treatment of Active Microscopic Colitis

A Randomized, Dose Ranging Trial of Mesalmine for the Treatment of Active Microscopic Colitis.

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
70 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Subjects must be 18 years old and older, have diarrhea and microscopic colitis. Pregnant or nursing females are excluded. They can't have other untreated diarrheal conditions. Subjects will receive medication for 8 weeks, followed by sigmoidoscopy with biopsies. The subjects will be monitored weekly. A pathologist will review pre and post treatment biopsies. Subjects that show improvement will be followed for 4 weeks post medication.

Detailed description

We propose a prospective, randomized trial of mesalamine at 1.2g and 4.8g doses for the treatment of microscopic colitis. Our hypothesis is mesalamine is safe and effective for the treatment of diarrhea in microscopic colitis and that the 4.8g dose is more effective than the 1.2g dose. We will recruit 70 subjects. The subjects will be randomized into to two groups, 4.8g dose, and 1.2g dose groups. Subjects will receive medication for 8 weeks, followed by sigmoidoscopy with biopsies. The subjects will be monitored weekly. A pathologist will review pre and post treatment biopsies. Responders will be followed for 4 weeks post medication. Subjects must be 18 years old and older, have diarrhea and microscopic colitis. Subjects will be excluded if they have unsuccessful treatment or side effects to 5-ASA drugs, oral corticosteroids, or salicylate. and antibiotics, mesalamine, bismuth or steroid use in the last two weeks. Subjects may not be on anticholinergics, cholestyramine, digoxin. Pregnant or nursing females are excluded. They can't have other untreated diarrheal conditions. A two-sample z-score test for proportions will be used to test whether relief rates are different between groups.

Conditions

Interventions

TypeNameDescription
DRUGMesalamine

Timeline

Start date
2007-02-01
Primary completion
2007-11-01
Completion
2007-11-01
First posted
2009-08-06
Last updated
2011-05-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00952952. Inclusion in this directory is not an endorsement.